A webcast showcasing long-term efficacy and safety data for both baricitinib and ixekizumab provided the opportunity for local rheumatologists to gain further insights into the data and discuss its relevance to clinical practice. The webcast was sponsored by Eli Lilly, and the discussion was moderated by Professor Bruce Kirkham, Professor of Translational Rheumatology from Kings ...
Insights on the long-term use of baricitinib and ixekizumab
7 Apr 2021
Sponsored by Eli Lilly Australia Pty Ltd